Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision-making.

about

Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision-making.

Item

http://www.wikidata.org/entity/Q38896473

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Management of relapsed and ref ...... w agents into decision-making.

@en

type

Item

label

Management of relapsed and ref ...... w agents into decision-making.

@en

prefLabel

Management of relapsed and ref ...... w agents into decision-making.

@en

P1476

Management of relapsed and ref ...... ew agents into decision-making

@en

P2093

Charles A Clark

http://www.w3.org/2001/XMLSchema#string

Jae Chung

http://www.w3.org/2001/XMLSchema#string

Luciano J Costa

http://www.w3.org/2001/XMLSchema#string

Robert F Cornell

http://www.w3.org/2001/XMLSchema#string

P2860

Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity

Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Salvage second hematopoietic cell transplantation in myeloma

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

P304

1044-1051

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.24478

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Emma C Scott

P577

2016-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27415608

http://www.w3.org/2001/XMLSchema#string